The company headquartered near Boston, MA, Charles River LaboratoriesÃƒ‚Ã¢€Ã¢„Ãƒ‚¢ 8000 employees serves clients in more than 50 countries. They are a global provider of solutions that advance the drug discovery and development process. Their leading edge products and services are designed to enable their clients to bring drugs to market faster and more efficiently. Backed by their rigorous, best in class procedures and their proven data collection, analysis and reporting capabilities, their products and services are organized into three categories spanning every step of the drug development pipeline, Research Models and Services, Preclinical Services, and Clinical Services.
Outsourcing helps pharmaceutical and biotech companies put more drug candidates in the pipeline, move those compounds through the pipeline faster and at the same time control development costs. In many cases, the research programs at pharmaceutical companies are operating at or near capacity. Outsourcing helps them to pursue the development of a greater number of compounds without taking on the added capital expense of constructing new facilities, hiring new people, and outfitting new labs with expensive equipment. In addition, outsourcing allows pharmaceutical and biotech companies to focus their internal R&D assets on core activities.
Charles River Laboratories has over 20 years of experience performing GLP infusion toxicology studies for the pharmaceutical and biotechnology industries. From their facilities in Canada, the UK and the US, they can undertake continuous and intermittent intravenous infusion studies and subcutaneous infusion studies across a wide variety of study durations.
Charles River Laboratories has been performing developmental and reproductive toxicity studies for pharmaceutical and biotechnology products for over 25 years. Using internationally recognized guidelines including International Conference of Harmonization guidelines, they offer overall developmental and reproductive toxicology program planning and individual study design to conduct safety assessments for clientÃƒ‚Ã¢€Ã¢„Ãƒ‚¢s products. Since the emergence of the biotechnology industry in the mid1980s, Charles River Laboratories has tested a broad range of biologics and can customize protocols to meet your individual requirements.
With a unique commitment to biomedical technology, including medical devices and combination products, Charles RiverÃƒ‚Ã¢€Ã¢„Ãƒ‚¢s Interventional and Surgical Services business unit combines unmatched scientific and technical expertise, customer service, a mature regulatory program and state of the art facilities to help accelerate your preclinical program. They offer specific expertise in the areas of interventional medicine, cardiothoracic and general surgery, cardiovascular pharmacology, orthopedics, ophthalmology, and medical device pathology.
Charles River Laboratories IncPosted on Apr 18, 2006